In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome
View ORCID ProfileJeroen Creemers, Ankur Ankan, View ORCID ProfileKit C.B. Roes, Gijs Schröder, View ORCID ProfileNiven Mehra, View ORCID ProfileCarl G. Figdor, View ORCID ProfileI. Jolanda M. de Vries, View ORCID ProfileJohannes Textor
doi: https://doi.org/10.1101/2021.09.09.21263319
Jeroen Creemers
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
2Oncode Institute, Nijmegen, The Netherlands
Ankur Ankan
3Data Science group, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands
Kit C.B. Roes
4Department of Health Evidence, Section Biostatistics, Radboudumc, Nijmegen, The Netherlands
Gijs Schröder
3Data Science group, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands
Niven Mehra
5Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
Carl G. Figdor
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
2Oncode Institute, Nijmegen, The Netherlands
I. Jolanda M. de Vries
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
Johannes Textor
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
3Data Science group, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
The code is available at GitHub: https://github.com/jeroencreemers/in-silico-clinical-trials
Posted January 30, 2023.
In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome
Jeroen Creemers, Ankur Ankan, Kit C.B. Roes, Gijs Schröder, Niven Mehra, Carl G. Figdor, I. Jolanda M. de Vries, Johannes Textor
medRxiv 2021.09.09.21263319; doi: https://doi.org/10.1101/2021.09.09.21263319
In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome
Jeroen Creemers, Ankur Ankan, Kit C.B. Roes, Gijs Schröder, Niven Mehra, Carl G. Figdor, I. Jolanda M. de Vries, Johannes Textor
medRxiv 2021.09.09.21263319; doi: https://doi.org/10.1101/2021.09.09.21263319
Subject Area
Subject Areas
- Addiction Medicine (408)
- Allergy and Immunology (720)
- Anesthesia (214)
- Cardiovascular Medicine (3042)
- Dermatology (258)
- Emergency Medicine (456)
- Epidemiology (12963)
- Forensic Medicine (12)
- Gastroenterology (848)
- Genetic and Genomic Medicine (4772)
- Geriatric Medicine (440)
- Health Economics (747)
- Health Informatics (3028)
- Health Policy (1096)
- Hematology (405)
- HIV/AIDS (952)
- Medical Education (450)
- Medical Ethics (119)
- Nephrology (490)
- Neurology (4544)
- Nursing (242)
- Nutrition (671)
- Oncology (2364)
- Ophthalmology (666)
- Orthopedics (264)
- Otolaryngology (332)
- Pain Medicine (296)
- Palliative Medicine (86)
- Pathology (512)
- Pediatrics (1232)
- Primary Care Research (515)
- Public and Global Health (7136)
- Radiology and Imaging (1587)
- Respiratory Medicine (940)
- Rheumatology (456)
- Sports Medicine (396)
- Surgery (504)
- Toxicology (63)
- Transplantation (218)
- Urology (187)